Analysts Set aTyr Pharma Inc (NASDAQ:LIFE) Price Target at $14.18

Shares of aTyr Pharma Inc (NASDAQ:LIFE) have earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $14.18.

Separately, ValuEngine raised shares of aTyr Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd.

LIFE stock traded down $0.15 during mid-day trading on Tuesday, hitting $3.21. The stock had a trading volume of 82,634 shares, compared to its average volume of 218,544. The company has a quick ratio of 4.00, a current ratio of 4.00 and a debt-to-equity ratio of 0.31. aTyr Pharma has a 52 week low of $3.12 and a 52 week high of $12.32. The stock’s fifty day moving average is $3.02.

aTyr Pharma (NASDAQ:LIFE) last released its earnings results on Monday, May 13th. The biotechnology company reported ($2.52) EPS for the quarter, beating the consensus estimate of ($3.22) by $0.70.

An institutional investor recently raised its position in aTyr Pharma stock. Wedbush Securities Inc. lifted its stake in shares of aTyr Pharma Inc (NASDAQ:LIFE) by 158.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 67,270 shares of the biotechnology company’s stock after purchasing an additional 41,271 shares during the quarter. Wedbush Securities Inc. owned 2.05% of aTyr Pharma worth $25,000 as of its most recent filing with the Securities and Exchange Commission.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.

Further Reading: Does a trade war provide a risk to the global economy?

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.